VAXCYTE INC's ticker is PCVX and the CUSIP is 92243G108. A total of 201 filers reported holding VAXCYTE INC in Q3 2023. The put-call ratio across all filers is 0.83 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $123,253 | +12.6% | 2,417,652 | +10.3% | 0.02% | +20.0% |
| Q2 2023 | $109,489 | +9016.5% | 2,192,382 | +6745.2% | 0.02% | – |
| Q1 2023 | $1,201 | -17.2% | 32,028 | +5.8% | 0.00% | – |
| Q4 2022 | $1,451 | -99.3% | 30,268 | +254.0% | 0.00% | – |
| Q3 2022 | $206,000 | -32.0% | 8,551 | -38.6% | 0.00% | – |
| Q2 2022 | $303,000 | -1.3% | 13,928 | +9.6% | 0.00% | – |
| Q1 2022 | $307,000 | +11.2% | 12,708 | +9.7% | 0.00% | – |
| Q4 2021 | $276,000 | -12.1% | 11,581 | -6.5% | 0.00% | – |
| Q3 2021 | $314,000 | +34.8% | 12,381 | +19.8% | 0.00% | – |
| Q2 2021 | $233,000 | – | 10,339 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Medicxi Ventures Management (Jersey) Ltd | 1,049,893 | $53,523,545 | 17.09% |
| Pivotal bioVenture Partners Investment Advisor LLC | 793,036 | $40,429,128 | 16.12% |
| Kynam Capital Management, LP | 1,302,407 | $66,396,709 | 10.86% |
| RA Capital Management | 7,891,254 | $402,296,129 | 7.92% |
| COMMODORE CAPITAL LP | 1,100,000 | $56,078,000 | 6.56% |
| GREAT POINT PARTNERS LLC | 531,211 | $27,081,137 | 4.93% |
| ACUTA CAPITAL PARTNERS, LLC | 121,022 | $6,169,702 | 4.14% |
| Frazier Life Sciences Management, L.P. | 1,164,405 | $59,361,367 | 3.94% |
| Novo Holdings A/S | 845,000 | $43,078,100 | 3.18% |
| BRAIDWELL LP | 1,619,553 | $82,564,812 | 2.61% |